Medication info
Tigedemiride Tablet 2 Milligrams

Tigedemiride Tablet 2 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Glimepiride›2mg / 1 tablet
Manufacturer / importer
Taeguk Pharmaceutical Co., Ltd.
Appearance
Green rectangular tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200805496 · Notified 2008.05.16 · Insurance code 644806090

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose should be adjusted individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is administered orally once daily. It should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration For patients who have not previously received medication, initiate treatment with 1 mg of glimepiride once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. Generally, there is little additional effect with doses above 4 mg, but some patients have achieved better metabolic control by increasing the dose to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic agent. 2) Subsequent dose adjustment As diabetes control may improve as treatment progresses, the amount of this medicine needed may decrease. Therefore, dose reduction or discontinuation of this medicine may be necessary to avoid hypoglycemia. Dose adjustment should also be considered when weight loss, changes in lifestyle, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral hypoglycemic agent to this medicine There is no exact dose equivalence between this medicine and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this medicine, it is advisable to follow the method described under Initial dose. That is, start at 1 mg daily and adjust the dose at intervals of 1 ~ 2 weeks. The potency and duration of action of the previously administered medication should be taken into consideration. 4) Dose adjustment While taking this medicine, blood glucose and/or urine glucose levels should be measured regularly, and regular measurement of glycosylated hemoglobin (HbA1c) levels is also recommended. In general, hypoglycemia can be promptly controlled by immediately ingesting sugar. Hypoglycemia may recur even after it has been successfully managed initially during treatment with a sulfonylurea. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate treatment and follow-up by a physician and may sometimes require hospitalization. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure, and is used when fasting blood glucose (FBG) is greater than 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal. Start insulin at a low dose and increase it approximately weekly according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin doses should be adjusted periodically while measuring blood glucose and glycosylated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each medication. However, efforts should be made to determine the minimum effective dose of each medication for blood glucose control. There is a risk of hypoglycemia when this medicine is administered concomitantly with metformin, and the risk may be increased. Appropriate caution should be exercised.

Ingredients

Manufacturer
Taeguk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Abnormal blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used to assist in blood sugar control for patients with type 2 diabetes. It is administered as an adjunct therapy alongside dietary and exercise therapies, and it can also be used as a monotherapy. If blood sugar control is not sufficiently achieved with oral hypoglycemic agents, it can be used in conjunction with insulin, and in cases where sulfonylurea or metformin monotherapy is inadequate, this medication can be combined with metformin. This medication improves blood sugar control and aids in diabetes management.

How to take

Adult dose

The dose should be adjusted individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is administered orally once daily. It should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration For patients who have not previously received medication, initiate treatment with 1 mg of glimepiride once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. Generally, there is little additional effect with doses above 4 mg, but some patients have achieved better metabolic control by increasing the dose to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic agent. 2) Subsequent dose adjustment As diabetes control may improve as treatment progresses, the amount of this medicine needed may decrease. Therefore, dose reduction or discontinuation of this medicine may be necessary to avoid hypoglycemia. Dose adjustment should also be considered when weight loss, changes in lifestyle, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral hypoglycemic agent to this medicine There is no exact dose equivalence between this medicine and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this medicine, it is advisable to follow the method described under Initial dose. That is, start at 1 mg daily and adjust the dose at intervals of 1 ~ 2 weeks. The potency and duration of action of the previously administered medication should be taken into consideration. 4) Dose adjustment While taking this medicine, blood glucose and/or urine glucose levels should be measured regularly, and regular measurement of glycosylated hemoglobin (HbA1c) levels is also recommended. In general, hypoglycemia can be promptly controlled by immediately ingesting sugar. Hypoglycemia may recur even after it has been successfully managed initially during treatment with a sulfonylurea. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate treatment and follow-up by a physician and may sometimes require hospitalization. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure, and is used when fasting blood glucose (FBG) is greater than 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal. Start insulin at a low dose and increase it approximately weekly according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin doses should be adjusted periodically while measuring blood glucose and glycosylated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each medication. However, efforts should be made to determine the minimum effective dose of each medication for blood glucose control. There is a risk of hypoglycemia when this medicine is administered concomitantly with metformin, and the risk may be increased. Appropriate caution should be exercised.

Precautions

This medication should not be used in patients with insulin-dependent diabetes, diabetic ketoacidosis, or those in a state of coma. Additionally, patients who have had allergic reactions to this medication or its components, or similar medications should not be administered this drug. There is no experience administering this medication to patients with severely impaired liver or kidney function, and in such cases, switching to insulin therapy is recommended. Women who are pregnant or may become pregnant, as well as those who are breastfeeding, should not take this medication. In patients with severe infections, prior to and after surgery, or those suffering from major injuries, it is advisable to apply insulin therapy. Patients with gastrointestinal disturbances such as diarrhea or vomiting should be cautious, as inadequate food absorption may increase the risk of hypoglycemia. This medication contains lactose and should not be administered to patients with genetic conditions like galactose intolerance, lactase deficiency, or glucose-galactose malabsorption. During the first week, there is a higher risk of hypoglycemia, and caution is especially needed for the elderly, patients with poor nutritional status or irregular eating habits, those who frequently consume alcohol, and patients with impaired kidney or liver function. Symptoms of hypoglycemia may include headache, severe hunger, nausea, fatigue, anxiety, confusion, blurred vision, dizziness, drowsiness, loss of consciousness, etc., and immediate sugar intake or notification to healthcare professionals is necessary if these symptoms occur. Early in treatment, visual disturbances or gastrointestinal symptoms may occur, and rarely abnormalities in liver function, blood disorders, or allergic reactions may arise; if abnormal symptoms occur, consult a physician immediately. For optimal blood sugar control, it is essential to take this medication regularly at designated times, adhere to dietary therapy, and exercise, and quickly consume sugar if hypoglycemia occurs. When taken with other medications, interactions may affect blood sugar control, so it is crucial to inform the physician or pharmacist of all medications currently being used. Pregnant or breastfeeding women should receive insulin therapy instead of this medication, as it may affect the fetus or newborn. In the case of overdose, severe hypoglycemia may occur, requiring immediate medical attention, and in emergencies, intravenous glucose may be required. The safety and effectiveness of this medication in children have not been established, and dosage adjustments are necessary for the elderly, considering decreased kidney function. Finally, store this medication out of children's reach and keep it in its original container to ensure safety.

Side effects

Hypoglycemia, headache, severe hunger, nausea, vomiting, fatigue, sleep, sleep disorder, anxiety, aggressiveness, decreased concentration, decreased agility or drive, depression, confusion, speech abnormalities, aphasia, visual disturbances, tremors, partial paralysis, sensory disturbances, dizziness, weakness, loss of self-control, temporary mental confusion, cerebral convulsions, drowsiness, loss of consciousness, coma, shallow breathing, bradycardia, sweating, cold and clammy skin, tachycardia, hypertension, palpitations, angina, deep vein thrombosis, blurred vision, fullness or pressure in the upper abdomen, abdominal pain, diarrhea, increased liver enzymes, liver dysfunction, bile secretion disorders, jaundice, hepatitis, thrombocytopenia, leukopenia, hemolytic anemia, anemia, neutropenia, agranulocytosis, pancytopenia, itching, urticaria, rash, dyspnea, hypotension, shock, anaphylaxis, angioedema, skin and mucous membrane syndrome, allergic vasculitis, photosensitivity reactions of the skin, decreased serum sodium concentration, taste disorders, hair loss, weight gain, dizziness, liver dysfunction, abdominal pain, arthralgia, dyspepsia, facial edema, impotence, flushing, gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. Additionally, it must be stored at room temperature between 1 and 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Green rectangular tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.